Method for diagnosing a hemoglobin-related disorder
The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as β-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free α-Hb pool in a biological sample obtained from said subject.
1. A method for monitoring a treatment against a hemoglobin disorder with an imbalance in the synthesis of hemoglobin chain in a subject in need thereof, said method comprising:
contacting blood samples obtained from said subject, before and after administration of said treatment to said subject, with Alpha-Hemoglobin Stabilizing Protein (AHSP) to bind free monomeric alpha hemoglobin (α-Hb),
detecting and/or quantifying the presence of AHSP-bound free monomeric α-Hb in said blood samples, and
correlating said amount of the AHSP-bound free monomeric α-Hb with monitoring of a treatment against said hemoglobin disorder in said subject,
wherein said treatment is determined to be effective for use as treatment of said hemoglobin disorder in said subject when the amount of the AHSP-bound free monomeric α-Hb detected and/or quantified in said subject after administration of said treatment is decreased as compared to the amount of the AHSP-bound free monomeric α-Hb detected and/or quantified in said subject before administration of said treatment and
wherein said treatment is determined to be ineffective for use as treatment of said hemoglobin disorder in said subject when the amount of the AHSP-bound free monomeric α-Hb detected and/or quantified in said subject after administration of said treatment is the same or increased as compared to the amount of the AHSP-bound free monomeric α-Hb detected and/or quantified in said subject before administration of said treatment.
2. The method according to claim 1 , wherein the step of detecting and/or quantifying the AHSP-bound free monomeric α-Hb is carried out by photometry.
3. The method according to claim 1 , wherein the step of detecting and/or quantifying the AHSP-bound free monomeric α-Hb is carried out by immunological detection.
4. The method according to claim 3 , wherein the immunological detection of the AHSP-bound free monomeric α-Hb is carried out by using at least one antibody that binds specifically to α-Hb.
5. The method according to claim 3 , wherein the immunological detection of the AHSP-bound free monomeric α-Hb is carried out by an enzyme immunoassay or enzyme-linked immunoassay (EIA or ELISA).
6. The method according to claim 3 , wherein the immunological detection of the AHSP-bound free monomeric α-Hb is carried out by homogeneous time resolved fluorescence (HTRF).
7. The method according to claim 1 , wherein the treatment against said haemoglobin disorder with an imbalance in the synthesis of hemoglobin chain is selected from the group consisting of treatment with iron, treatment with erythropoietin, treatment with cobalamin, and treatment with γ chain synthesis stimulating agent.
8. The method according to claim 1 , wherein the hemoglobin-disorder with an imbalance in the synthesis of hemoglobin chain is selected from the group consisting of β-thalassemia, γ-thalassemia, syndromic thalassemia conditions, anemia, sickle cell disease, unstable Hb variants and hereditary persistence of fetal Hb.
9. The method according to claim 1 , wherein the hemoglobin-disorder with an imbalance in the synthesis of hemoglobin chain is β-thalassemia.
10. The method according to claim 1 , wherein the AHSP-bound free monomeric α-Hb is detected with a kit comprising:
a solid support, and
an α-Hb-specific binding partner coated to the solid support.